Nov. 12, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company ... into ...

Q3 2024 Earnings Call Transcript October 31, 2024 Vir Biotechnology, Inc. misses on earnings expectations. Reported EPS is ...

Q3 2024 Earnings Call Transcript October 29, 2024 Nautilus Biotechnology, Inc. beats earnings expectations. Reported EPS is $ ...

These risks and uncertainties and risks associated with our business are described in the company's reports filed with the Securities and Exchange Commission, including Forms 10-K, 10-Q and 8-K.

Revenue: Revenue for the three months ended September 30, 2024, increased to approximately $1,958,000 compared to $397,000 ...

COPENHAGEN, Denmark, October 31, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, provides business up ...

Explore the role and challenges of AAV characterization, the significance of capsid filling, and the best methods to enhance gene therapy.

3. It has plenty of financial flexibility Viking isn't a biotech that will need to take out a lot of debt ... It could easily tap outside help in multiple forms As if its strong balance sheet weren't ...

Compass Pathways plc has exciting developments in treating treatment-resistant depression with the innovative COMP360. Click ...

One of the most magnificent stocks healthcare investors can buy for the long haul is U.K.-based AstraZeneca, which is trading at around $76 right now. The company has a robust business that generates ...

Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today reported its financial results for the ...

3). These are incredibly illiquid ... But in a world without a viable biotech IPO market, the only realistic exit for shareholders is some form of an acquisition by a larger firm.